Immutep Limited
IMMPImmutep Ltd (formerly Prima Biomed) is a biotechnology company working primarily in the field of cancer immunotherapy using the LAG3 immune control mechanism. The company was originally built on CVac, a therapeutic cancer vaccine. In late 2014 the privately held French immunotherapy company Immutep SA was purchased by Prima Biotech.
Drugs in Pipeline
4
Phase 3 Programs
3
Upcoming Catalysts
3
Next Catalyst
Oct 2026
Market Overview
Stock performance and key metrics
3 upcoming, 0 past
pembrolizumab (KEYTRUDA®)
NSCLC
eftilagimod alfa
Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
eftilagimod alpha
Breast Carcinoma
IMP321 (eftilagimod alpha)
Adenocarcinoma Breast Stage IV
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
pembrolizumab (KEYTRUDA®) | Phase 3 | NSCLC | - | - |
eftilagimod alfa | Phase 3 | Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) | - | - |
eftilagimod alpha | Phase 3 | Breast Carcinoma | - | - |
IMP321 (eftilagimod alpha) | Phase 2 | Adenocarcinoma Breast Stage IV | - | - |